Navigation Links
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
Date:2/11/2009

t; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended October 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                             Media
    info@peregrineinc.com                                 Barbara Lindheim
    (800) 987-8256                                        (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Despite a policy focus on expanding access ... vulnerable population continues to have significant dental disease. ... of the American Dental Association , researchers from ... School of Dental Medicine report on the first ... care provided by caregivers to adults with developmental ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Phoseon Technology, ... , continues to expand the business worldwide. This rapid ... with additional capacity for manufacturing efforts. The company has ... last five years and expects this growth to continue ... curing technology gains worldwide adoption. , “We are ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... 2014 Diet Doc understands that many of ... weight and their dieting attempts could be easily sabotaged by ... hormone diet treatments into their programs as a way ... fast and effective weight loss results, it also allows patients ... to maintain their weight for the future. , Earlier versions ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... offers Barry McMillen - Nicotine Cessation Expert and ... ... Using tobacco isn,t just a,habit; it,s an addiction. Hazelden has ... 50 years. The same principles,of the Hazelden treatment experience help tobacco ...
... University Hospitals Case Medical Center finds that Deep ... Tourette Syndrome (TS). This first-of-its-kind study of five ... tic frequency and severity in some people who ... is a neurobehavioral disorder characterized by sudden, repetitive ...
... sent to kill them, study finds , , MONDAY, Nov. ... of molecular weapons that helps make community-associated methicillin-resistant ... work must be done, the study "provides a partial ... causing infection and gives a starting point in the ...
... contribute to high mercury,levels in fish Americans consume, ... dental mercury air,emissions may be more than five times ... The U.S. House,Subcommittee on Domestic Policy of the ... Wednesday, Nov. 14, to discuss FDA,s,responsibility to evaluate the ...
... 12 Indiana Gov. Mitch,Daniels joined executives from ... to announce the company,s plans to build the ... Indiana, filling a growing,nationwide demand for lower-cost medicines. ... 2009, will cover an area equivalent to,six and ...
... AdCare Health,Systems, Inc. (Amex: ADK ) announced ... results on Wednesday, November 14th, 2007. In conjunction,with ... call on November,15th, at 4:15 EST. The telephone ... unable to participate at that time, playback is,available ...
Cached Medicine News:Health News:Quit Smoking Tips For The Great American Smokeout Day - November 15 2Health News:University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 2Health News:University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 3Health News:Key to MRSA Virulence in Community Discovered 2Health News:Key to MRSA Virulence in Community Discovered 3Health News:Environmental Impacts of Dental Mercury Focus of U.S. House Oversight Hearing Wednesday 2Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 2Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 3Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 4Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 5Health News:AdCare Health Systems, Inc. Announces 2007 Third Quarter Earnings Release and Conference Call Schedule 2
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014   ... today the appointment of J. Patrick Ravenel ... years of enterprise software and systems experience and a ... Fortune 500 companies. "Patrick has been ... class software and systems and is known industry-wide for ...
(Date:10/1/2014)...  SI-BONE, Inc., a medical device company that pioneered the ... invasive surgical (MIS) device indicated for fusion for certain disorders ... its European operations with the formation of a GmbH and ... Manager, Germany.  Mr. Schaber will join former Kyphon colleague ... , Middle East and Asia ...
(Date:10/1/2014)... LAUSANNE , Switzerland , October ... European leader in Clinical Genomics and Next Generation Sequencing ... Solution allowing clinicians to run full cystic fibrosis analysis ... covers the identification and characterisation of all types of ... analytical performance. Until now, it has not ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
Improve your refractive outcome, with AXIS II precision biometry A-scan. Biometry clinically proven as accurate as partial coherence interferometry while not limited by dense media....
... with graphic display and IOL power ... combination units include firmware module with ... II formulas. Audible tones increase in ... visual axis. Constant tone when alignment ...
... ("I-cubed") is an exceptionally high resolution, ... oscilloscope (static deflection) display. This provides ... low cost video monitors. Vitreous structures ... cells, as well as tumor vascularity ...
... sensitive B-scan system which quickly identifies ocular asymmetry. ... eyes differ by more than 0.3 mm, a ... The B5500 enables quick and easy identification of ... or inserting shells under the lids. The B5500 ...
Medicine Products: